Latest stories on BMRN
BioMarin options imply 3.4% move in share price post-earnings
The Fly50 · neutralearnings
BioMarin CEO: We’re pursuing more rare disease deals
CNBC63 · neutralproduct/pr
BioMarin CEO Alexander Hardy: We're an at-scale leader in rare diseases
CNBC63 · neutralproduct/pr
BioMarin's Pipeline Excitement Is Real but Does It Justify the Profitability Wait
Barchart54 · neutralgeneral
3 Healthcare Stocks with Strong Buy Ratings and Double-Digit Upside
TipRanks64 · neutralanalyst
BioMarin price target lowered to $122 from $124 at Morgan Stanley
The Fly38 · neutralanalyst
BioMarin price target raised to $87 from $86 at JPMorgan
The Fly63 · neutralanalyst
BioMarin assumed with a Buy at UBS
The Fly63 · neutralanalyst
BioMarin price target raised to $114 from $111 at Barclays
The Fly63 · neutralanalyst
Raymond James upgrades BioMarin stock to strong buy on valuation
Investing.com Analyst Ratings67 · bullishanalyst
BioMarin to present ‘encouraging’ results from studies of voxzogo at ASBMR
The Fly61 · neutralproduct/pr
BioMarin Q3 financial results to see IPR&D expense impact of $283M
Seeking Alpha34 · bearishearnings
BIOMARIN PHARMACEUTICAL INC (BMRN) files 8-K
SEC 8-K50 · neutralgeneral
BioMarin names Cara Bauer as Chief People Officer
The Fly55 · neutralgeneral
BioMarin Appoints Cara Bauer as Chief People Officer
PR Newswire55 · neutralgeneral
BioMarin reports five-year Pompe disease data showing durable motor function
CNBC67 · bullishproduct/pr
BioMarin announces five-year Phase 3 data for POMBILITI plus OPFOLDA
The Fly59 · neutralproduct/pr
BioMarin Grants Ascendis Global License, Secures Royalty Revenues
TipRanks63 · neutralm&a
BIOMARIN PHARMACEUTICAL INC (BMRN) files 8-K
SEC 8-K50 · neutralgeneral
BioMarin: Why I See Significant Upside Into 2027
Seeking Alpha67 · bullishanalyst